Tyrosinkinaseinhibitoren in der Tumortherapie - Teil 2

Nach erfolgreichen präklinischen Studien haben einige Tyrosinkinase-Inhibitoren (TKI) bereits Eingang in die klinische Praxis gefunden. Der anti-HER-2 monoklonale Antikörper (mAb) Trastuzumab bei der Behandlung des Mammakarzinoms sowie der BCR-ABL-Tyrosinkinaseinhibitor Imatinib bei der Behandlung der chronischen myeolischen Leukämie (CML) sind hochwirksam und führten zur Entwicklung und Evaluation weiterer molekularer TKI. Zur Zeit befinden sich mindestens 30 TKI weltweit in verschiedenen präklinischen sowie klinischen Studien zur Behandlung von malignen Erkrankungen (s. Tab. 1 in Teil 1: Dtsch Med Wochenschr 2005; 130 (21): 1321). Nachfolgend wird der klinische Stellenwert verschiedener TKI diskutiert.

Literatur

• 1 Agus D B. et al . Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.  Cancer Cell. 2002;  2 127-137
• 2 Apperley J F. et al . Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.  N Engl J Med. 2002;  347 481-487
• 3 Arteaga C L. Selecting the right patient for tumor therapy.  Nat Med. 2004;  10 577-578
• 4 Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.  J Clin Invest. 2003;  111 1287-1295
• 5 Ciardiello F. et al . Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.  Clin Cancer Res. 2000;  6 2053-2063
• 6 Cunningham D. et al . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 337-345
• 7 Demetri G D. et al . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.  N Engl J Med. 2002;  347 472-480
• 8 Griffin R J. et al . Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.  Cancer Res. 2002;  62 1702-1706
• 9 Herbst R S, Shin D M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.  Cancer. 2002;  94 1593-1611
• 10 Hurwitz H. et al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
• 11 Kantarjian H M. et al . Long-Term Survival Benefit and Improved Complete Cytogenetic and Molecular Response Rates with Imatinib Mesylate in Philadelphia Chromosome-Positive, Chronic-Phase Chronic Myeloid Leukemia after Failure of Interferon-{alpha}.  Blood. 2004;  15 15
• 12 Ross D M, Hughes T P. Cancer treatment with kinase inhibitors: what have we learnt from imatinib?.  Br J Cancer. 2004;  90 12-19
• 13 Slamon D J. et al . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  N Engl J Med. 2001;  344 783-792
• 14 Terre C. et al . Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.  Leukemia. 2004;  18 1340-1346
• 15 von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.  Lancet. 2002;  359 487-491
• 16 Wood J M. et al . PTK787/ZK 222 584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.  Cancer Res. 2000;  60 2178-2189
• 17 Xiong H Q. et al . Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.  J Clin Oncol. 2004;  22 2610-2616